X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA CIPLA ALEMBIC PHARMA/
CIPLA
 
P/E (TTM) x 21.5 33.2 64.6% View Chart
P/BV x 5.1 2.9 174.8% View Chart
Dividend Yield % 0.7 0.6 114.6%  

Financials

 ALEMBIC PHARMA   CIPLA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
CIPLA
Mar-18
ALEMBIC PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs645663 97.3%   
Low Rs470479 98.1%   
Sales per share (Unadj.) Rs166.1189.0 87.9%  
Earnings per share (Unadj.) Rs21.917.6 124.5%  
Cash flow per share (Unadj.) Rs27.534.0 80.8%  
Dividends per share (Unadj.) Rs4.003.00 133.3%  
Dividend yield (eoy) %0.70.5 136.6%  
Book value per share (Unadj.) Rs117.8176.7 66.6%  
Shares outstanding (eoy) m188.52805.12 23.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 111.1%   
Avg P/E ratio x25.532.5 78.4%  
P/CF ratio (eoy) x20.316.8 120.8%  
Price / Book Value ratio x4.73.2 146.5%  
Dividend payout %18.317.1 107.1%   
Avg Mkt Cap Rs m105,090459,724 22.9%   
No. of employees `000NA23.6 0.0%   
Total wages/salary Rs m6,22826,901 23.2%   
Avg. sales/employee Rs ThNM6,446.1-  
Avg. wages/employee Rs ThNM1,139.4-  
Avg. net profit/employee Rs ThNM600.0-  
INCOME DATA
Net Sales Rs m31,308152,193 20.6%  
Other income Rs m703,577 2.0%   
Total revenues Rs m31,378155,769 20.1%   
Gross profit Rs m6,43128,264 22.8%  
Depreciation Rs m1,05513,228 8.0%   
Interest Rs m341,142 3.0%   
Profit before tax Rs m5,41317,470 31.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m-81-28 291.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m1,2042,501 48.1%   
Profit after tax Rs m4,12814,166 29.1%  
Gross profit margin %20.518.6 110.6%  
Effective tax rate %22.214.3 155.3%   
Net profit margin %13.29.3 141.7%  
BALANCE SHEET DATA
Current assets Rs m18,247108,141 16.9%   
Current liabilities Rs m11,23538,322 29.3%   
Net working cap to sales %22.445.9 48.8%  
Current ratio x1.62.8 57.6%  
Inventory Days Days8697 88.2%  
Debtors Days Days6174 82.5%  
Net fixed assets Rs m20,035109,411 18.3%   
Share capital Rs m3771,610 23.4%   
"Free" reserves Rs m21,824140,682 15.5%   
Net worth Rs m22,201142,292 15.6%   
Long term debt Rs m5,00036,621 13.7%   
Total assets Rs m39,411228,606 17.2%  
Interest coverage x160.216.3 983.2%   
Debt to equity ratio x0.20.3 87.5%  
Sales to assets ratio x0.80.7 119.3%   
Return on assets %10.66.7 157.7%  
Return on equity %18.610.0 186.8%  
Return on capital %19.710.0 198.2%  
Exports to sales %46.432.8 141.6%   
Imports to sales %10.50-   
Exports (fob) Rs m14,53549,883 29.1%   
Imports (cif) Rs m3,288NA-   
Fx inflow Rs m14,72251,691 28.5%   
Fx outflow Rs m7,02621,033 33.4%   
Net fx Rs m7,69630,658 25.1%   
CASH FLOW
From Operations Rs m3,12414,628 21.4%  
From Investments Rs m-8,844-8,540 103.6%  
From Financial Activity Rs m5,026-3,855 -130.4%  
Net Cashflow Rs m-6932,431 -28.5%  

Share Holding

Indian Promoters % 74.1 16.0 463.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 2.9 12.2 23.8%  
FIIs % 9.1 23.7 38.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 13.9 26.2 53.1%  
Shareholders   49,328 161,166 30.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; IT & Energy Stocks Gain(Closing)

Indian share markets traded on a volatile note throughout the day and ended their session on a flat note. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

Follow a Super Investor Like This to Multiply Your Wealth(The 5 Minute Wrapup)

Jan 4, 2019

Following a super investor can certainly help build a portfolio and create wealth in the long term.

15 Mistakes to Avoid to Make a Killing in the Markets(Profit Hunter)

Jan 3, 2019

Richa dissects the common mistakes investors make and how to avoid and even take advantage of them.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 16, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - TTK HEALTHCARE COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS